-
Mashup Score: 4
Living with stage 4 kidney cancer has taught me to embrace the present, cherish connection and find gratitude each day in unexpected places.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Synchronous bilateral Wilms tumors are prone to develop independently and respond differently to preoperative chemotherapy - 27 day(s) ago
What’s new? Wilms tumor (WT), which accounts for about 90% of childhood kidney cancers, occurs bilaterally in fewer than 10% of cases. However, bilateral WT is generally more aggressive than unilater…
Source: onlinelibrary.wiley.comCategories: General Medicine NewsTweet-
NOW ONLINE! New research shows that the left and right tumors in bilateral Wilms tumor—an aggressive form of childhood #KidneyCancer — can be genetically distinct and respond differently to chemotherapy. 🔒FULL ACCESS ➡️ https://t.co/m4hdVXkxpw https://t.co/rgqZv4SX8q
-
-
Mashup Score: 0
Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. https://t.co/YoZDhDO2ns #kidneycancer
-
-
Mashup Score: 0
Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. https://t.co/YoZDhDO2ns #kidneycancer
-
-
Mashup Score: 2From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey | GU Oncology Now - 1 month(s) ago
Dr. Brugarolas reflects on his lab’s role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Source: www.guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
Dr. @JBrugarolas of @UTSWMedCenter talks about his journey to becoming a #kidneycancer specialist in a new interview, highlighting key breakthroughs, his lab’s role in developing HIF-2 inhibitors, and his ongoing work to improve patient outcomes: https://t.co/5tP1I87Fko
-
-
Mashup Score: 0
According to the American Cancer Society approximately 76,080 new cases of kidney cancer will occur in the U.S. in 2021 and 13,780 people will die from the disease. [1] The most common form of kidney cancer, renal cell carcinoma (RCC), has the highest mortality among genitourinary tumors, with an approximate five-year survival rate of 76% globally. [2] Incidence rates for RCC have risen steadily each year since the 1990s in most of the world, partly due to improved detection via newer imaging tests, [3]
Source: cdmrp.health.milCategories: General Medicine News, Oncologists1Tweet-
Support and apply for Kidney Cancer Research! We need funding to continue ! https://t.co/LRP0YfeGqd Support advocacy groups! @KidneyCancer @kidneycan @Joeyswings @kidneycoa #kidneycancer
-
-
Mashup Score: 12
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Source: www.guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Watch our new roundtable on the latest research and practice updates related to advanced #kidneycancer. 👉 @DrKarineTawagi was joined by Drs. @ReginaBarCar, @maughanonc, @AlbigesL, and David McDermott for this insightful discussion: https://t.co/yESWdSs8TC https://t.co/35BxrRmTIj
-
-
Mashup Score: 2Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis - 3 month(s) ago
All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along with surgery and surveillance, to individualise treatment decisions in these patients. Future research should aim to conduct randomised controlled trials across larger patient populations to further elucidate the long-term oncological and survival outcomes associated with these treatments.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
RT @_ShankarSiva: 📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! https://t.co/v4fXO17tLp. SABR vs thermal ablation; - Despite ⏫age…
-
-
Mashup Score: 108Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis - 3 month(s) ago
All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along with surgery and surveillance, to individualise treatment decisions in these patients. Future research should aim to conduct randomised controlled trials across larger patient populations to further elucidate the long-term oncological and survival outcomes associated with these treatments.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
RT @_ShankarSiva: 📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! https://t.co/v4fXO17tLp. SABR vs thermal ablation; - Despite ⏫age…
-
-
Mashup Score: 103Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis - 3 month(s) ago
All investigated ablative methods continue to represent effective treatment choices in renal cell carcinoma, and these findings support multi-disciplinary discussions of these treatment methods, along with surgery and surveillance, to individualise treatment decisions in these patients. Future research should aim to conduct randomised controlled trials across larger patient populations to further elucidate the long-term oncological and survival outcomes associated with these treatments.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
RT @_ShankarSiva: 📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! https://t.co/v4fXO17tLp. SABR vs thermal ablation; - Despite ⏫age…
-
Living with stage 4 #KidneyCancer has taught me to embrace the present, cherish connection and find gratitude each day in unexpected places. https://t.co/HCYrEicMK9